

## Neurocrine Biosciences to Participate at Investor Conferences in September

August 28, 2024

Morgan Stanley 22<sup>nd</sup> Annual Global Healthcare Conference on September 4 in New York

2024 Wells Fargo Healthcare Conference on September 5 in Boston

SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at two upcoming investor conferences in September.



- Chief Executive Officer Kevin Gorman, Chief Business Development and Strategy Officer Kyle Gano, and Chief Financial Officer Matt Abernethy will present at the Morgan Stanley 22<sup>nd</sup> Annual Global Healthcare Conference in New York at 3:20 p.m. Eastern Time on Wednesday, September 4, 2024.
- Kyle Gano and Matt Abernethy will present at the 2024 Wells Fargo Healthcare Conference in Boston at 8:45 a.m. Eastern Time on Thursday, September 5, 2024.

The live presentations will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at <a href="https://www.neurocrine.com">www.neurocrine.com</a>. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

## **About Neurocrine Biosciences**

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis\* and uterine fibroids\*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (\*in collaboration with AbbVie)

The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

C View original content to download multimedia: <a href="https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-september-302233393.html">https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-september-302233393.html</a>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc., Tony Jewell (Media), 858-617-7578, media@neurocrine.com, Todd Tushla (Investors), 858-617-7143, ir@neurocrine.com